The expertise of our Senior Advisors and Scientific Advisory Board is vital in elucidating the therapeutic potential and marketability of overseas drug candidates, thereby ensuring the existence of a strong and diverse development platform. By maintaining close ties with a network of foreign firms, SymBio is actively building a bridge for development in Japan and Asia-Pacific Rim countries, and filling a void for unaddressed patient needs.

(As of April/1/2023)

✖